in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.
Contact:Joshua T. Brumm
Executive Vice President, Finance
Phone: 408-215-3311
Ramses Erdtmann
Vice President of Investor Relations
Phone: 408-215-3325Pharmacyclics, Inc.
Condensed Consolidated Balance Sheets
(unaudited; in thousands)
December 31,June 30, 20122012AssetsCash, cash equivalents and marketable securities 1
$
317,114$
203,607Other current assets 2
29,3789,788Total current assets
346,492213,395Property and equipment, net
6,4033,842Other assets
2,2341,883Total assets
$
355,129$
219,120Liabilities and Stockholders' EquityDeferred revenue - current portion
$
8,139$
8,054Other current liabilities
21,11810,932Total current liabilities
29,25718,986Deferred revenue - non-current portion
62,56267,324Deferred rent
784687Total liabilities
92,60386,997Stockholders' equity
262,526132,123Total liabilities and stockholders' equity
$
355,129$
219,1201Marketable securities
$
9,681$
5,7112As of December 31, 2012 and June 30, 2012, Other current assets includes $26.6 million and $5.8 million, respectively, due to t
'/>"/>
SOURCE Pharmacyclics, Inc. Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related biology technology :1.
Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting2.
Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs3.
Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 20114.
Interleukin Genetics Reports Third Quarter 2011 Financial Results5.
Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders6.
Nile Therapeutics Reports 2011 Third Quarter Financial Results7.
Pharmasset Reports Fiscal Year End 2011 Financial Results8.
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 20119.
SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results10.
WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy11.
Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies